Skip to playerSkip to main contentSkip to footer
  • 10/2/2024
Eli Lilly's valuation stands at $842 billion, 54x projected earnings. Orforglipron could be the first small-molecule weight-loss pill when it launches in 2026, giving Eli Lilly two-year lead before rivals catch

Recommended